Boehringer Ingelheim Archives | Page 2 of 3

Home / Posts tagged Boehringer Ingelheim (Page 2)

First Half of 2024: Boehringer Ingelheim Progresses Pipeline at Pace and Reaches Major Milestones

Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, and pulmonary fibrosis Strong first half net sales growth of 7.4%* year on year Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it [...]

Boehringer Ingelheim Produces Its Own Green Energy

German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plant Ingelheim site can cover 95% of its energy needs from renewable sources New power plant helps achieve the company’s global climate targets and saves around 50,000 tons of CO2 per year Boehringer Ingelheim inaugurated a biomass power plant at its Ingelheim [...]

Boehringer Ingelheim’s Survodutide Shows Breakthrough Improvement in Liver Fibrosis with No Worsening of MASH in 64.5% of Patients with F2 and F3 Fibrosis

News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%). New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH.1 Additional sub-analysis shows [...]

Outdated Perceptions and Practices Fuelling Mental Health Crisis, New Economist Impact Study Reveals

International analysis of mental health provision in eight G20 countries reveals stigma, a shortage of mental health professionals and inconsistent availability and quality of care are creating barriers to vital mental health care services New research highlights global and country-level insights into where action is needed alongside recommendations for measures aimed at addressing these challenges [...]

Boehringer Ingelheim Shares Positive Results from the First Study Worldwide in Diabetic Macular Ischemia

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed [...]

Boehringer Ingelheim Reports Strong Growth in 2023 and Accelerates Late-stage Pipeline

Human Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV® Animal Health sales up 6.9 %* to EUR 4.7 bn, fueled by new product launches R&D expenditures increase by 14.2% to EUR 5.8 bn Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key [...]

SPEVIGO® Approved for Expanded Indications in China and the US

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4 In China, SPEVIGO®’s expanded approval adds the reduction of occurrences of GPP in pediatric patients aged 12 and above weighing ≥40 kg, and adults5 The US FDA’s approval expands the use [...]

Survodutide Phase II Trial Shows 83% of Adults Treated Achieved Groundbreaking Results in Liver Disease Due to MASH, with Significant Improvements in Fibrosis

Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus placebo in a Phase II trial Survodutide, a novel glucagon/GLP-1 receptor dual agonist, has demonstrated efficacy in people with obesity1, and statistically significant results in MASH2 suggest the potential to [...]

New Collaboration Between Boehringer Ingelheim and Sleip Leverages AI-technology to Help Detect Lameness in Horses

The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone. A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses. This partnership delivers on the shared commitment of Boehringer and Sleip [...]

Boehringer Expands Production Site in Greece for New Medicine

Ingelheim am Rhein, Germany, Jan. 11 (Korea Bizwire) – Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications. Main disease areas include cardio-renal-metabolic (CRM) diseases, [...]